We are live on ! Find out more
OVID icon

Ovid Therapeutics
OVID

62 hedge funds and large institutions have $73.7M invested in Ovid Therapeutics in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 22 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

480% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 5

340% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 5

177% more capital invested

Capital invested by funds: $26.6M → $73.7M (+$47.1M)

63% more funds holding

Funds holding: 38 → 62 (+24)

15.93% more ownership

Funds ownership: 21.21% → 37.15% (+16%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
62
Holders Change
+24
Holders Change %
+63.16%
% of All Funds
1.22%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
29
Increased
22
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CCM
Consonance Capital Management
New York
+$9.12M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$6.58M
3
Axa
Axa
France
+$2.74M
4
Citigroup
Citigroup
New York
+$1.58M
5
Renaissance Technologies
Renaissance Technologies
New York
+$1.57M

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$5.01M
2
Marshall Wace
Marshall Wace
United Kingdom
-$59K
3
MWNA
Marshall Wace North America
New York
-$41K
4
WG
Winton Group
United Kingdom
-$34K
5
Northern Trust
Northern Trust
Illinois
-$24.9K
Name Holding Trade Value Shares
Change 		Change in
Stake
William Blair & Company
26
William Blair & Company
Illinois
$790K +$601K +190,253 New
Two Sigma Investments
27
Two Sigma Investments
New York
$700K +$532K +168,602 New
ECM
28
ExodusPoint Capital Management
New York
$613K +$467K +147,740 New
FC
29
Fairpointe Capital
Illinois
$588K +$129K +40,700 +40%
OAM
30
Oxford Asset Management
United Kingdom
$528K +$156K +49,401 +64%
RG
31
Redmile Group
California
$506K – – –
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$483K +$367K +116,335 New
Dimensional Fund Advisors
33
Dimensional Fund Advisors
Texas
$376K – – –
LCM
34
Laurion Capital Management
New York
$374K +$285K +90,236 New
Goldman Sachs
35
Goldman Sachs
New York
$355K +$157K +49,580 +138%
BFM
36
Boothbay Fund Management
New York
$314K -$11.5K -3,657 -5%
VF
37
Virtu Financial
New York
$305K +$154K +48,865 +198%
Assenagon Asset Management
38
Assenagon Asset Management
Luxembourg
$274K +$208K +65,906 New
Northern Trust
39
Northern Trust
Illinois
$211K -$24.9K -7,895 -13%
OGC
40
One68 Global Capital
New York
$210K +$160K +50,662 New
6CM
41
683 Capital Management
New York
$175K +$133K +42,088 New
Citadel Advisors
42
Citadel Advisors
Florida
$158K +$120K +38,088 New
ARTA
43
A.R.T. Advisors
New York
$146K +$111K +35,162 New
CSS
44
Cubist Systematic Strategies
Connecticut
$108K +$82.1K +25,991 New
Squarepoint
45
Squarepoint
New York
$108K +$82.2K +26,029 New
Deutsche Bank
46
Deutsche Bank
Germany
$96K +$40.7K +12,896 +126%
AG
47
Algert Global
California
$81K +$61.9K +19,590 New
Two Sigma Advisers
48
Two Sigma Advisers
New York
$80K +$60.6K +19,200 New
TRCT
49
Tower Research Capital (TRC)
New York
$79K +$60.2K +19,063 New
Charles Schwab
50
Charles Schwab
California
$78K +$58.7K +18,578 New
1
2
3

OVID Hedge Fund Activity: Q4 2019 in Review

62 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Ovid Therapeutics (OVID) for Q4 2019, worth a combined $73.7M — up 177% from $26.6M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new OVID positions and 5 closed out — a net gain of 24 holders — while 22 added to existing stakes and 5 trimmed.

The largest buyer was Consonance Capital Management, opening a new position worth an estimated $9.12M. The largest seller was BVF Inc, cutting an estimated $5.01M.

  • 62 institutional investors held Ovid Therapeutics (OVID) as of Q4 2019, up from 38 in Q3 2019.
  • Funds reported $73.7M of Ovid Therapeutics stock for Q4 2019, up 177% quarter-over-quarter.
  • 29 funds opened new Ovid Therapeutics positions in Q4 2019 and 5 closed out, a net change of +24 holders.
  • The largest Ovid Therapeutics buyer in Q4 2019 was Consonance Capital Management, an estimated $9.12M added.
  • The largest Ovid Therapeutics seller in Q4 2019 was BVF Inc, an estimated $5.01M sold.

Based on aggregated 13F filings for Q4 2019.